Clinical Trials Sponsored by BioMAS Ltd

Total 19039 results

BioMAS Ltd

Withdrawn

Topical Application of AS101 for the Treatment of Psoriasis

Mild to Moderate Psoriasis

Israel
BioMAS Ltd

Suspended

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Israel
BioMAS Ltd

Terminated

Topical Application of AS101 for the Treatment of Atopic Dermatitis

Atopic Dermatitis

Israel
BioMAS Ltd

Completed

Safety and Efficacy Study to Test Topical AS101 for External Genital Warts

Condyloma Acuminata | Wart; External Genital Organs

Israel
BioMAS Ltd

Unknown

Safety and Efficacy Double Blind Vehicle Controlled Study of 15% AS101 Gel to Treat External Genital Warts

External Genital Warts

Israel
BioMAS Ltd

Terminated

Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients

Chemotherapy Induced Thrombocytopenia

Israel
Zimmer Biomet
Biomet U.K. Ltd.

Terminated

Retrieval Study and Histological Examination Of A Hip Femoral Components With Hydroxyapatite Coatings

Femoral Neck Fractures

United Kingdom
Zimmer Biomet
Biomet U.K. Ltd.

Terminated

ReCap Total Hip Resurfacing Prospective Data Collection

Arthritis

United Kingdom
Zimmer Biomet
Biomet U.K. Ltd.

Completed

A Randomized Control Trial to Assess Early Clinical and Functional Outcome of the ROCC and LCS Total Knee Implant Designs

Osteoarthritis

United Kingdom
Zimmer Biomet
Biomet U.K. Ltd.

Completed

A Clinical Evaluation of Metal Ion Release From Metal-on-Metal Cementless Total Hip Arthroplasty

Osteoarthritis | Rheumatoid Arthritis | Avascular Necrosis | Traumatic Arthritis

United Kingdom
Zimmer Biomet
Biomet U.K. Ltd.

Withdrawn

Retrospective Data Review of ReCap Total Hip Resurfacing

Osteoarthritis of the Hip
Biotax Labs LTD

Recruiting

Microbiome Test for the Detection of Colorectal Polyps

Colon Polyp

Israel
Prima BioMed Ltd

Completed

Ovarian Cancer Vaccine for Patients in Remission

Epithelial Ovarian Cancer

United States, Australia
Prima BioMed Ltd

Withdrawn

Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas

Pancreatic Carcinoma Stage I | Pancreatic Carcinoma Stage II
BioCis Pharma Ltd

Completed

Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis

Atopic Dermatitis

Finland
Remedor Biomed Ltd

Completed

Topical Erythropoietin Hydrogel Formulation for Diabetic Foot Ulcers (Remede d'Or)

Diabetic Foot Ulcer

Israel
Prima BioMed Ltd

Completed

Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (CAN-003X)

Epithelial Ovarian Cancer

United States, Australia
Prima BioMed Ltd

Terminated

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (CANVAS)

Epithelial Ovarian Cancer

United States, Australia
Shanghai Biomabs Pharmaceutical Co., Ltd.

Recruiting

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .

Postmenopausal Osteoporosis

China
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers

Postmenopausal Osteoporosis

China
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

Asthma, Allergic

China
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD

Wet Age-related Macular Degeneration

China
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis

Rheumatoid Arthritis

China
BioRay Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

China
BioRay Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BRY805 in Participants With Advanced Solid Tumors

Advanced Solid Tumor

China
BioRay Pharmaceutical Co., Ltd.

Not yet recruiting

Clinical Study of 1A46 Drug Substance

Advanced Malignancies

China
UnicoCell Biomed CO. LTD

Recruiting

Efficacy and Safety of ELIXCYTE Intra-articular Injection in Subject With Knee Osteoarthritis

Knee Osteoarthritis

Taiwan
Beijing StarMab Biomed Technology Ltd

Recruiting

Clinical Study of SM3321 With Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Nanjing Leads Biolabs Co.,Ltd

Recruiting

A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Harbour BioMed (Guangzhou) Co. Ltd.

Recruiting

A Trial of HBM9378 in Healthy Chinese Subjects

Asthma

China
Nanjing Leads Biolabs Co.,Ltd

Recruiting

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Malignant Tumors

China
Nanjing Leads Biolabs Co.,Ltd

Recruiting

A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors

Advanced Solid Tumor

China
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

Solid Tumors
Nanjing Leads Biolabs Co.,Ltd

Recruiting

Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors

Advanced Solid Tumor

China
Harbour BioMed (Guangzhou) Co. Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease

Thyroid Ophthalmopathy

China
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Solid Tumor
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab

Solid Tumors
Harbour BioMed (Guangzhou) Co. Ltd.

Completed

A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

Myasthenia Gravis

China
Harbour BioMed (Guangzhou) Co. Ltd.

Completed

A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye

Dry Eye

China
T&R Biofab Co., Ltd.

Unknown

A Clinical Study to Evaluate the Safety and Efficacy of Surgical Material for Nasal Septoplasty

Nasal Obstruction | Septal Deformity

Korea, Republic of
Zimmer Biomet
Hvidovre University Hospital; Biomet U.K. Ltd.

Withdrawn

Clinical Evaluation on HA Coated Dynamic Hip Screws for Trochanteric Femoral Fractures

Osteoarthritis
Nanjing Leads Biolabs Co.,Ltd

Recruiting

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Advanced Neuroendocrine Carcinoma

China
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Myasthenia Gravis

China
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors

Solid Tumors
Nanjing Leads Biolabs Co.,Ltd

Recruiting

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

Advanced Melanoma

China
MiCo BioMed Co., Ltd.
Syntactx

Completed

TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood

SARS-CoV2 Infection

United States
Harbour BioMed (Guangzhou) Co. Ltd.

Completed

A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers

Healthy Chinese Volunteers

China
T&R Biofab Co., Ltd.

Unknown

Clinical Extend Study to Evaluate Safety and Effectiveness of TnR Nasal Mesh for Correction of Nasal Septum on Patients

Nasal Obstruction | Septal Deformity
BioLab 612 LLC
Cleveland BioLabs, Inc.

Unknown

Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer

Colorectal Cancer

Russian Federation
BioLab 612 LLC
Cleveland BioLabs, Inc.

Completed

Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis

Breast Cancer

3

Subscribe